{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:32:33Z","timestamp":1790681553124,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.cmi.2016.08.017","type":"journal-article","created":{"date-parts":[[2016,9,10]],"date-time":"2016-09-10T00:56:28Z","timestamp":1473468988000},"page":"990-995","source":"Crossref","is-referenced-by-count":53,"title":["Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study"],"prefix":"10.1016","volume":"22","author":[{"given":"B.","family":"Gergely Szabo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Kadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Szidonia Lenart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dezsenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kunovszki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kamotsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Nikolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Prinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.08.017_bib1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of america (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"Stuart","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2016.08.017_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection","volume":"20","author":"Debast","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2016.08.017_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","article-title":"Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections","volume":"108","author":"Surawicz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2016.08.017_bib4","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/592257","article-title":"Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078","volume":"47","author":"Goorhuis","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.017_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1086\/588294","article-title":"Editorial Commentary: decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?","volume":"47","author":"Kuijper","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.017_bib6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/0003-4819-145-10-200611210-00008","article-title":"Narrative Review: the new epidemic of Clostridium difficile\u2013associated enteric disease","volume":"145","author":"Bartlett","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2016.08.017_bib7","first-page":"96","article-title":"Activity of tigecycline against recent European clinical isolates of Clostridium difficile","volume":"35","author":"Hawser","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.08.017_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.anaerobe.2013.02.003","article-title":"In\u00a0vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden","volume":"20","author":"Rashid","year":"2013","journal-title":"Anaerobe"},{"key":"10.1016\/j.cmi.2016.08.017_bib9","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1469-0691.2009.03048.x","article-title":"In\u00a0vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden","volume":"16","author":"Noren","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2016.08.017_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/AAC.00839-10","article-title":"Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production","volume":"55","author":"Jump","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2016.08.017_bib11","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/jac\/dkl364","article-title":"Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model","volume":"58","author":"Baines","year":"2006","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2016.08.017_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ijantimicag.2014.11.016","article-title":"Tigecycline exhibits inhibitory activity against Clostridium difficile in the intestinal tract of hospitalised patients","volume":"45","author":"Kundrapu","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2016.08.017_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/ggi.12336","article-title":"Use of tigecycline in elderly patients for Clostridium difficile infection","volume":"15","author":"Fantin","year":"2015","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.cmi.2016.08.017_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijid.2014.04.025","article-title":"Tigecycline for severe Clostridium difficile infection","volume":"26","author":"Thomas","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.017_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40121-014-0050-x","article-title":"Tigecycline for the treatment of severe and severe complicated Clostridium difficile infection","volume":"3","author":"Britt","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2016.08.017_bib16","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1345\/aph.1Q080","article-title":"Tigecycline for the treatment of severe Clostridium difficile infection","volume":"45","author":"Larson","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.cmi.2016.08.017_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/702910","article-title":"Refractory Clostridium difficile Infection successfully treated with tigecycline, rifaximin, and vancomycin","volume":"2012","author":"Lao","year":"2012","journal-title":"Case Rep Med"},{"key":"10.1016\/j.cmi.2016.08.017_bib18","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/599224","article-title":"Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection","volume":"48","author":"Herpers","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.017_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.cmi.2016.08.017_bib20","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cmi.2016.08.017_bib21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00134-003-1662-x","article-title":"2001 SCCM\/ESICM\/ACCP\/ATS\/SIS International Sepsis Definitions Conference","volume":"29","author":"Levy","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2016.08.017_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2334-13-148","article-title":"Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy","volume":"13","author":"Miller","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2016.08.017_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijantimicag.2015.03.012","article-title":"Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature","volume":"46","author":"Di Bella","year":"2015","journal-title":"Int J Antimicrob Agents"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16303561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16303561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T15:20:46Z","timestamp":1536420046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16303561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1198743X16303561"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.08.017","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}